CS
CCCC icon

Credit Suisse’s C4 Therapeutics CCCC Stock Holding History

Credit Suisse’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,997
Closed -$81.6K – 3178
2023
Q1 		$81.6K Buy
25,997
+8
+0% +$47 ﹤0.01% 3219
2022
Q4 		$153K Buy
25,989
+1,959
+8% +$16.2K ﹤0.01% 3247
2022
Q3 		$211K Buy
24,030
+12,366
+106% +$128K ﹤0.01% 3221
2022
Q2 		$88K Buy
11,664
+1,740
+18% +$15.3K ﹤0.01% 3560
2022
Q1 		$240K Buy
9,924
+636
+7% +$15.4K ﹤0.01% 3323
2021
Q4 		$298K Buy
9,288
+758
+9% +$30K ﹤0.01% 4114
2021
Q3 		$380K Sell
8,530
-58
-0.7% -$2.48K ﹤0.01% 3979
2021
Q2 		$324K Buy
+8,588
New +$308K ﹤0.01% 4080

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Credit Suisse's CCCC Position: Q2 2023 in Review

Credit Suisse sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 25,997 shares — an estimated $81.6K sold.

Credit Suisse first reported a position in CCCC in Q2 2021 and held it in 8 quarters. The position peaked at $380K in Q3 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Credit Suisse reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 25,997 C4 Therapeutics shares in Q2 2023, an estimated $81.6K.
  • Credit Suisse first reported a position in C4 Therapeutics in Q2 2021 and held it in 8 quarters.
  • Credit Suisse's C4 Therapeutics position peaked at $380K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.